In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.See omnystudio.com/listener for privacy information.